Synergistic Cholestatic Disease Management System

A novel system integrating elafibranor treatment with AI, IoT, blockchain, and new materials to provide personalized, data-driven management of cholestatic diseases

The original patent addressed the treatment of cholestatic diseases, specifically PBC and PSC, with elafibranor. However, it did not provide a comprehensive solution for monitoring, predicting, and adapting to disease progression. The new inventive concept addresses this limitation by incorporating distinct technologies to create a more powerful system

The system comprises a wearable device for tracking patient biomarkers, an AI-powered analytics module for predicting disease progression, and a personalized treatment planner integrating elafibranor administration with lifestyle recommendations. Additionally, the system incorporates machine learning algorithms for optimizing elafibranor treatment, a blockchain-based platform for secure data management, a smart pillbox system for ensuring patient adherence, and a novel biomaterial composition for oral delivery of elafibranor

The new claims introduce a synergistic combination of distinct technologies, providing a holistic approach to cholestatic disease management. The inventive step lies in the integration of these technologies to create a more effective and personalized treatment system

Alternative embodiments could include different AI algorithms, various wearable devices, or alternative blockchain platforms. Variations could also include integrating the system with electronic health records or telemedicine platforms

The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine, digital health, and disease management